Xbrane Biopharma AB Cash Flow Reinvestment Rate
Xbrane Biopharma AB cash flow reinvestment rate. Xbrane Biopharma AB (XBRANE) has a Cash Flow Reinvestment Rate of 0.37x as of December 2024, reinvesting Skr34.60 Million (capex Skr17.30 Million plus investments Skr-17.30 Million) from operating cash flow of Skr93.91 Million. Explore Xbrane Biopharma AB cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Xbrane Biopharma AB (2018–2018)
Cash flow reinvestment rate of Xbrane Biopharma AB from 2018 to 2018. Historical reinvestment intensity for Xbrane Biopharma AB across 1 annual periods. Explore Xbrane Biopharma AB capital spending ratio to see what proportion of operating cash flow is directed to capital expenditures.
Xbrane Biopharma AB Cash Flow Reinvestment Rate by Year (2018–2018)
Xbrane Biopharma AB cash flow reinvestment rate by year from 2018 to 2018. Year-by-year capital reinvestment analysis for Xbrane Biopharma AB. For the full cash flow conversion analysis, see XBRANE cash generation efficiency.
| Year | Reinvestment Rate | Total Reinvested (SEK) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2018 | 0.07x | Skr3.20 Million | Skr46.71 Million | Skr1.60 Million | — |